153 related articles for article (PubMed ID: 34047449)
1. Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies.
Tsoukas MA; Cohen E; Legault L; von Oettingen JE; Yale JF; Vallis M; Odabassian M; El Fathi A; Rutkowski J; Jafar A; Ghanbari M; Gouchie-Provencher N; René J; Palisaitis E; Haidar A
Diabetes Obes Metab; 2021 Sep; 23(9):2090-2098. PubMed ID: 34047449
[TBL] [Abstract][Full Text] [Related]
2. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
[TBL] [Abstract][Full Text] [Related]
3. Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada.
Cohen E; Tsoukas MA; Legault L; Vallis M; Von Oettingen JE; Palisaitis E; Odabassian M; Yale JF; Garfield N; Gouchie-Provencher N; Rutkowski J; Jafar A; Ghanbari M; Haidar A
Lancet Digit Health; 2024 Jul; 6(7):e489-e499. PubMed ID: 38906614
[TBL] [Abstract][Full Text] [Related]
4. Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial.
Haidar A; Yale JF; Lovblom LE; Cardinez N; Orszag A; Falappa CM; Gouchie-Provencher N; Tsoukas MA; El Fathi A; Rene J; Eldelekli D; Lanctôt SO; Scarr D; Perkins BA
Diabetes Obes Metab; 2021 Jun; 23(6):1272-1281. PubMed ID: 33528904
[TBL] [Abstract][Full Text] [Related]
5. Fully Automated Artificial Pancreas for Adults With Type 1 Diabetes Using Multiple Hormones: Exploratory Experiments.
Majdpour D; Tsoukas MA; Yale JF; El Fathi A; Rutkowski J; Rene J; Garfield N; Legault L; Haidar A
Can J Diabetes; 2021 Dec; 45(8):734-742. PubMed ID: 33888413
[TBL] [Abstract][Full Text] [Related]
6. A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial.
Haidar A; Tsoukas MA; Bernier-Twardy S; Yale JF; Rutkowski J; Bossy A; Pytka E; El Fathi A; Strauss N; Legault L
Diabetes Care; 2020 Mar; 43(3):597-606. PubMed ID: 31974099
[TBL] [Abstract][Full Text] [Related]
7. A Simplified Semiquantitative Meal Bolus Strategy Combined with Single- and Dual-Hormone Closed-Loop Delivery in Patients with Type 1 Diabetes: A Pilot Study.
Gingras V; Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
Diabetes Technol Ther; 2016 Aug; 18(8):464-71. PubMed ID: 27191385
[TBL] [Abstract][Full Text] [Related]
8. Study protocol for a randomised open-label clinical trial examining the safety and efficacy of the Android Artificial Pancreas System (AAPS) with advanced bolus-free features in adults with type 1 diabetes: the 'CLOSE IT' (Closed Loop Open SourcE In Type 1 diabetes) trial.
Wilkinson T; Tomic D; Boyle E; Burren D; Elghattis Y; Jenkins A; Keesing C; Middleton S; Nanayakkara N; Williman J; de Bock M; Cohen ND
BMJ Open; 2024 Feb; 14(2):e078171. PubMed ID: 38382954
[TBL] [Abstract][Full Text] [Related]
9. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study.
Boughton CK; Hartnell S; Thabit H; Poettler T; Herzig D; Wilinska ME; Ashcroft NL; Sibayan J; Cohen N; Calhoun P; Bally L; Mader JK; Evans M; Leelarathna L; Hovorka R
Diabetes Obes Metab; 2021 Jun; 23(6):1389-1396. PubMed ID: 33606901
[TBL] [Abstract][Full Text] [Related]
10. Fast-Acting Insulin Aspart Use with the MiniMed
Hsu L; Buckingham B; Basina M; Ekhlaspour L; von Eyben R; Wang J; Lal RA
Diabetes Technol Ther; 2021 Jan; 23(1):1-7. PubMed ID: 32520594
[No Abstract] [Full Text] [Related]
11. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.
Weinzimer SA; Sherr JL; Cengiz E; Kim G; Ruiz JL; Carria L; Voskanyan G; Roy A; Tamborlane WV
Diabetes Care; 2012 Oct; 35(10):1994-9. PubMed ID: 22815298
[TBL] [Abstract][Full Text] [Related]
12. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
Renukuntla VS; Ramchandani N; Trast J; Cantwell M; Heptulla RA
J Diabetes Sci Technol; 2014 Sep; 8(5):1011-7. PubMed ID: 25030181
[TBL] [Abstract][Full Text] [Related]
13. Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed
Grosman B; Wu D; Parikh N; Roy A; Voskanyan G; Kurtz N; Sturis J; Cohen O; Ekelund M; Vigersky R
Comput Methods Programs Biomed; 2021 Jun; 205():106087. PubMed ID: 33873075
[TBL] [Abstract][Full Text] [Related]
14. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P
Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882
[TBL] [Abstract][Full Text] [Related]
15. Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide.
Sherr JL; Patel NS; Michaud CI; Palau-Collazo MM; Van Name MA; Tamborlane WV; Cengiz E; Carria LR; Tichy EM; Weinzimer SA
Diabetes Care; 2016 Jul; 39(7):1127-34. PubMed ID: 27208332
[TBL] [Abstract][Full Text] [Related]
16. Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used.
King AB
Endocr Pract; 2009 Apr; 15(3):229-33. PubMed ID: 19364691
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients.
King AB
Diabetes Technol Ther; 2010 Feb; 12(2):105-8. PubMed ID: 20105039
[TBL] [Abstract][Full Text] [Related]
18. Long-term use of the hybrid artificial pancreas by adjusting carbohydrate ratios and programmed basal rate: A reinforcement learning approach.
Jafar A; Fathi AE; Haidar A
Comput Methods Programs Biomed; 2021 Mar; 200():105936. PubMed ID: 33515844
[TBL] [Abstract][Full Text] [Related]
19. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
[TBL] [Abstract][Full Text] [Related]
20. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
Ryan GJ; Jobe LJ; Martin R
Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
